This will be an open label multicenter study of the safety and efficacy of an active implantable VNS device in patients with Crohn's Disease.
Patients who complete study SPM-007 will be enrolled in this study at the time of the last visit of the preceding study. The assessments at the last visit of the preceding study will also be used as baseline measures for the current study. If the patient has previously discontinued SPM-007 and greater than 30 days have elapsed since the final visit in SPM-007, baseline measures for the current study will be repeated, and an interim medical history will be taken to assess whether any new medical conditions were diagnosed in the time between studies. The study will continue until the last patient entered has completed 24 months in this study. Follow-up visits will occur at 3, 6, 12, 18 and 24 months. A final follow-up visit will occur for all remaining patients at study closure when the final enrolled subject has completed 24 months on study. An Interim Visit must be performed a maximum of 1 month after any change in device settings. Interim visits may also be performed at any time at the principal investigator's discretion; either between scheduled visits, or after the patient has completed the Month 24 Visit, if the study is still ongoing.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Vagus nerve stimulation
Dubrava Hospital
Zagreb, Croatia
Humanitas Research Hospital
Milan, Italy
Academic Medical Center
Amsterdam, Netherlands
Karolinska Institute
Stockholm, Sweden
Crohn's Disease Activity Index
Time frame: 24 months
Inflammatory Bowel Disease Questionnaire
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.